Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial

Autor: Batmunkh, Tsetsegsaikhan, Moore, Kerryn A., Thomson, Helen, Altangerel, Bolor, Amraa, Otgonjargal, Avaa, Naranbaatar, Batbayar, Lkhagvagaram, Batsukh, Khishigjargal, Bright, Kathryn, Burentogtokh, Tsogjargal, Ha Do, Lien Anh, Dorj, Gantuya, Hart, John D., Javkhlantugs, Khulan, Jigjidsuren, Sarantsetseg, Justice, Frances, Li, Shuo, Licciardi, Paul V., Mashbaatar, Khaliunaa, Mazarakis, Nadia, Neal, Eleanor F.G., Nguyen, Cattram Duong, Ochirbat, Batbayar, Tsolmon, Bilegtsaikhan, Tuya, Alimaa, Surenjav, Unursaikhan, von Mollendorf, Claire, Mulholland, Kim
Zdroj: In The Lancet Regional Health - Western Pacific January 2024 42
Databáze: ScienceDirect